CMChristine Y. Malati

Christine Y. Malati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christine Y. Malati has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementation and resource needs for long‐acting PrEP in low‐ and middle‐income countries: a scoping review

    by Delivette Castor, Craig J. Heck, Daniela Quigee, Niharika Vasant Telrandhe, Kiran Kui, Jiaxin Wu, Elizabeth Glickson, Kibret Yohannes, Sergio Torres Rueda, Fiammetta Bozzani, et al.

    Introduction: Several low‐ and middle‐income countries (LMICs) are preparing to introduce long‐acting pre‐exposure prophylaxis (LAP). Amid multiple pre‐exposure prophylaxis (PrEP) options and constrained funding, decision‐makers could benefit from systematic implementation planning and aligned costs. We reviewed national costed implementation plans (CIPs) to describe relevant implementation inputs and activities (domains) for informing the costed rollout of LAP. We assessed how primary costing evidence aligned with those domains.Methods: We conducted a rapid review of CIPs for oral PrEP and family planning (FP) to develop a consensus of implementation domains, and a scoping review across nine electronic databases for publications on PrEP costing in LMICs between January 2010 and June 2022. We extracted cost data and assessed alignment with the implementation domains and the Global Health Costing Consortium principles.Results: We identified 15 implementation domains from four national PrEP plans and FP‐CIP template; only six were in all sources. We included 66 full‐text manuscripts, 10 reported LAP, 13 (20%) were primary cost studies‐representing seven countries, and none of the 13 included LAP. The 13 primary cost studies included PrEP commodities (n = 12), human resources (n = 11), indirect costs (n = 11), other commodities (n = 10), demand creation (n = 9) and counselling (n = 9). Few studies costed integration into non‐HIV services (n = 5), above site costs (n = 3), supply chains and logistics (n = 3) or policy and planning (n = 2), and none included the costs of target setting, health information system adaptations or implementation research. Cost units and outcomes were variable (e.g. average per person‐year).Discussion: LAP planning will require updating HIV prevention policies, technical assistance for logistical and clinical support, expanding beyond HIV platforms, setting PrEP achievement targets overall and disaggregated by method, extensive supply chain and logistics planning and support, as well as updating health information systems to monitor multiple PrEP methods with different visit schedules. The 15 implementation domains were variable in reviewed studies. PrEP primary cost and budget data are necessary for new product introduction and should match implementation plans with financing.Conclusions: As PrEP services expand to include LAP, decision‐makers need a framework, tools and a process to support countries in planning the systematic rollout and costing for LAP.


  • Open Access

    Implementation of a Global Health Equity fellowship established in partnership between an academic institution and governmental agency

    by Rakhi Karwa, Ellen Schellhase, Christine Y. Malati, Sonak D. Pastakia, Imran Manji, Jeffrey M. Samuel, Monica L. Miller

    Health disparities exist globally in high‐income and low‐ and middle‐income countries. They are driven by social determinants of health (SDOH). While a role for pharmacists in addressing SDOH exists, a lack of structured postgraduate training limits pharmacists from being equipped to build innovative programs and contribute to health policy on SDOH in an impactful way. Postgraduate training, specifically, fellowships provides opportunities for pharmacists to develop the needed skills for working with SDOH. The Purdue University College of Pharmacy (PUCOP)‐United States Agency for International Development (USAID) Global Health Equity Fellowship was developed to meet this training need. This 2‐y fellowship represents a partnership between USAID and PUCOP. During the fellowship, time is split between USAID in Washington DC, PUCOP in Indianapolis, Indiana, and the Purdue Kenya Partnership (PKP) in Eldoret, Kenya. The fellowship was developed with a foundation of core values, the creation of a logic model, strategic partnerships, maintaining an adaptable structure, and intentional partner communication. Fellow outcomes were evaluated in three categories: engagement, education, and scholarship. Fellows completed 10 experiential opportunities between three sites and participated in the development of new and supported ongoing care programs and policy implementation in both local and international settings. Fellows completed the following educational outcomes: completed an online Master of Public Health (MPH) through Purdue Global, provided 13 educational presentations and lectures at various sites, and precepted a total of 12 PUCOP advanced pharmacy practice experience (APPE) students and 16 Kenyan pharmacy interns and Master of Pharmacy (MPharm) students. Fellows completed three publications and two abstracts at international conferences. This established training model provides pharmacists with a structured path to gain the knowledge, skills, and attitudes to be leaders in addressing Global Health Equity.


  • Role of pharmacists in improving accessibility of antiretrovirals to support the United States President's Emergency Plan for AIDS Relief: Impact on the patient, program, and market

    by Christine Y. Malati

    The United States President's Emergency Plan for AIDS Relief (PEPFAR) is the largest commitment by any nation to combat a single disease through prevention and treatment initiatives; pharmacists play a critical role in improving the accessibility of antiretrovirals (ARVs). When determining the potential use of a medication for a human immunodeficiency virus (HIV) program, it is helpful to consider decisions through the (a) Perspective of a patient, (b) Perspective of the overarching HIV program providing care, and (c) Perspective of the ARV market. Pharmacists are uniquely positioned to contribute to decisions from these three perspectives. At the beginning of PEPFAR, the price of ARVs was cost prohibitive; however, after 17 years since its inception, through the work of pharmacists and other public health professionals, the price to treat one patient for one year is currently 63 USD. This article describes the impact of pharmacists at the U.S. Agency for International Development (USAID) and the Food and Drug Administration (FDA) in facilitating a dramatic reduction in the cost of ARVs, through the use of an expedited approval process and through pooling procurement of ARVs from a limited formulary.


  • Open Access

    Pursuing use of optimal formulations for paediatric HIV epidemic control – a look at the use of LPV/r oral pellets and oral granules

    by Christine Y Malati, Rachel Golin, Lisa O'BRien, Nandita Sugandhi, Meena Srivastava, Chris Larson, Benjamin R Phelps

    Introduction: Despite a significant reduction in mother‐to‐child transmission of HIV, an estimated 180,000 children were infected with HIV in 2017, and only 52% of children under 15 years of age living with HIV (CLHIV) are on life‐saving antiretroviral therapy (ART). Without effective treatment, half of CLHIV die before the age of two years and only one in five survives to five years of age.Discussion: Over the past four years, the United States Food and Drug Administration tentatively approved new formulations of lopinavir/ritonavir (LPV/r) in the form of oral pellets and oral granules. However, the slow uptake of the aforementioned formulations in the low‐ and middle‐income countries with the highest paediatric HIV burden is largely due to three challenges: limited manufacturing capacity; current unit cost of the pellets and granules; and slow uptake of these new formulations by policy makers and health care workers.Conclusions: Solutions to overcome these barriers include ensuring availability of an adequate supply of LPV/r oral pellets and oral granules, considering all programmatic and clinical factors when selecting paediatric ART formulations, and leveraging current resources to decrease paediatric HIV morbidity and mortality.